Additionally, sodium-glucose transporter 2 (SGLT2) inhibitors are promising for reducing the risk of adverse cardiovascular and renal outcomes in patients with CKD, with or without concomitant cardiovascular disease [12-14]. This evidence concerns the gene SLC5A2 and chronic kidney disease.